| News

Rhizen drug secures approval in the USA

10.02.2021

The United States Food and Drug Administration has granted accelerated approval for the drug Umbralisib. Basel biotech Rhizen has discovered this inhibitor for the treatment of cancer.

Swaroop Vakkalanka, President and CEO of Rhizen Pharmaceuticals (img: Rhizen)

Rhizen Pharmaceuticals has discovered Umbralisib, a medication that has now been approved by the US Food and Drug Administration (FDA) for the treatment of patients with certain types of marginal zone lymphoma (MZL) and follicular lymphoma (FL). Rhizen licensed the inhibitor to TG Therapeutics based in the USA, which also did its total clinical development. The Basel biotech has retained commercialization rights for India as well as being the manufacturing and supply partner for Umbralisib, as was reported in a press release.

Umbralisib is an oral, once daily, inhibitor of phosphoinositide 3 kinase delta and casein kinase 1 epsilon. “Umbralisib’s approval offers MZL and FL patients a new treatment option and is a huge validation of Rhizen’s drug discovery & development capabilities,“ said Swaroop Vakkalanka, President & CEO of Rhizen Pharmaceuticals, in the press release.

Rhizen relocated from La Chaux-de-Fonds in the canton of Neuchâtel to Basel in December 2020, with support from Basel Area Business & Innovation, the investment and innovation promotion agency. At the new main location in Basel, the clinical development and commercialization of the novel oncology and inflammation medicines are to be promoted. In particular, Rhizen wants to benefit from the proximity to the Basel Area life sciences cluster. It furthermore plans to grow and create local jobs, so the highly qualified talent offered by Basel was another key factor.

“Basel with its vibrant biotech and pharma ecosystem offers the best opportunity for Rhizen to expand and focus on clinical development of its rich pipeline of investigational drugs,” explained Vakkalanka.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Scailyte now calls Basel home
Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

Scailyte now calls Basel home

The biotechnology firm Scailyte is now installed at the Novartis Campus of Switzerland Innovation Park Basel Area. Scailyte develops solutions...

Read More
Roche gives MRI equipment a second life
Basel Area Business & Innovation, Innovation, Switzerland Innovation Park

Roche gives MRI equipment a second life

Basel-based pharmaceutical and diagnostics company Roche has decommissioned two MRI machines that are no longer in use. One complete device...

Read More
BGO Software establishes branch in Basel
Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

BGO Software establishes branch in Basel

The Bulgarian firm BGO Software has now established a presence in Basel after founding BGO Software und Technologie GmbH. The...

Read More
ACM Biosciences receives support for Covid-19 vaccine
Basel Area Business & Innovation, Innovation

ACM Biosciences receives support for Covid-19 vaccine

Innosuisse, the Swiss Innovation Agency, is supporting the Basel-based biotechnology company ACM Biosciences with a grant. This is intended for...

Read More
Basilea receives grant for novel antibiotic
Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

Basilea receives grant for novel antibiotic

The CARB-X initiative is granting a sum of 2.7 million US dollars to the Basel-based pharmaceuticals company Basilea. This will...

Read More
Discover the Basel Area as #1 in biotech investment
Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

Discover the Basel Area as #1 in biotech investment

A total of 700+ life science companies call the Basel Area their home. It has become the premier biotech cluster...

Read More
1 2 3 14

Do you have a question? We'd like to hear from you.